As a reminder, last year, we announced that we are no longer participating in the ACR Reach program as of January 1, 2024 and as of that date, it is being treated as discontinued operations in our reporting. That said, we expect to pay CMS around $39,000,000 in the second half of twenty twenty four relating to our prior ACR REIT participation, which is fully accrued as of March 31, 2024. We estimate our year end 2024 total restricted and unrestricted cash, cash equivalents and investments to be between $388,000,000 to $408,000,000 As a reminder, we ended 2023 with unregulated liquidity of $137,000,000 as well as an incremental $74,000,000 of capital and surplus in excess of minimum risk based capital requirements. This equates to a pro form a year end 2023 unregulated liquidity of $211,000,000 On the same basis, we expect pro form a year end 2024 unregulated liquidity of between $145,000,000 to $165,000,000 Overall, I believe Clover is very well positioned to succeed in both 2024 as well as into 2025 and beyond. Our strategy, while historically seen as unusual, is now arguably generating significantly better financial and clinical results than the traditional incumbents and in a way that is sustainably differentiated.